Recruiting

Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors

This project aims to adapt, implement, and evaluate PLA based intervention in Rural Kabul, Afghanistan for TIIDM prevention and control.

ClinicalTrials.gov IDNCT07350694
PhaseNA
Enrollment250
SponsorHealthNet Transcultural Psychosocial Organization
Age20 Years
SexALL
I'm interested View official listing

Conditions studied

Diabetes Type 2, Type II Diabetes Mellitus

About this study

This project aims to adapt, implement, and evaluate PLA based intervention in Rural Kabul, Afghanistan for TIIDM prevention and control.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * For intervention phase: Individuals aged 20 years and above. For baseline and endline assessments (before and after the intervention): Individuals aged 30 years and above. * Participants residing in the randomized clusters of Kabul, Afghanistan Individuals willing to participate in the study and provide consent. * All individuals with normoglycemia, intermediate hyperglycaemia, and diabetes are encouraged to participate. * Participants who can attend the scheduled meetings and interventions as per the study protocol. Exclusion Criteria: * For Intervention phase: Individuals below the age of 20 years. For baseline and endline assessments (before and after the intervention): individuals below the age of 30 years. * Individuals unwilling to provide consent for participation. * Participants with reported health conditions that may hinder their active involvement in the study. * Individuals with non-compliance with research protocols

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.